Specificity of serum neutralizing antibodies induced by transient immune suppression of inapparent carrier ponies infected with a neutralization-resistant equine infectious anemia virus envelope strain

Journal of General Virology

Volumn 86, Issue 1, 2005, Pages 139-149

  Howe, Laryssa ^a   Craigo, Jodi K ^b   Issel, Charles J ^c   Montelaro, Ronald C ^a,b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; EQUINE INFECTIOUS ANEMIA VIRUS; HORSE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS CARRIER; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, OUTBRED STRAINS; ANTIBODIES, VIRAL; CARRIER STATE; EQUINE INFECTIOUS ANEMIA; GLYCOPROTEINS; HORSES; IMMUNOCOMPROMISED HOST; INFECTIOUS ANEMIA VIRUS, EQUINE; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; VIRAL ENVELOPE PROTEINS;

EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS;

EID: 11444250826     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.80374-0     Document Type: Article

References (54)

1. Back, N. K., Smit, L., De Jong, J. J., Keulen, W., Schutten, M., Goudsmit, J. & Tersmette, M. (1994). An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199, 431-438.
2. Ball, J M., Rushlow, K. E., Issel, C. J. & Montelaro, R. C. (1992). Detailed mapping of the antigenicity of the surface unit glycoprotein of equine infectious anemia virus by using synthetic peptide strategies. J Virol 66, 732-742.
3. 3 domains glycoprotein compatibility is required for viral replication. Virus Res 79, 91-101.
4. SF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. J Virol 73, 5294-5300.
5. Craigo, J. K., Leroux, C., Howe, L., Steckbeck, J. D., Cook, S. J., Issel, C. J. & Montelaro, R. C. (2002). Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication. J Gen Virol 83, 1353-1359.
6. Fazekas de, St. Groth S. & Webster, R. G. (1966). Disquisitions of original antigenic sin. I. Evidence in man. J Exp Med 124, 331-345.
7. Good, M. F., Zevering, Y., Currier, J. & Bilsborough, J. (1993). 'Original antigenic sin', T cell memory, and malaria sporozoite immunity: an hypothesis for immune evasion. Parasite Immunol 15, 187-193.
8. Grund, C. H., Lechman, E. R., Pezzuolo, N. A., Issel, C. J. & Montelaro, R. C. (1996). Fine specificity of equine infectious anaemia virus gp90-specific antibodies associated with protective and enhancing immune responses in experimentally infected and immunized ponies. J Gen Virol 77, 435-442.
9. Hammond, S. A., Cook S. J., Lichtenstein, D. L., Issel, C. J. & Montelaro, R. C. (1997). Maturation of the cellular and Humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J Virol 71, 3840-3852.
10. Hammond, S. A., Raabe, M. L., Issel, C. J. & Montelaro, R. C. (1999). Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus. Virology 262, 416-430.
11. Hammond, S. A., Li, F., McKeon, B. M., Sr Cook, S. J., Issel, C. J. & Montelaro, R. C. (2000). Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus. J Virol 74, 5968-5981.
12. Harrold, S. M., Cook, S. J., Cook, R. F., Rushlow, K. E., Issel, C. J. & Montelaro, R. C. (2000). Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids. J Virol 74, 3112-3121.
13. Howe, L., Leroux, C., Issel, C. J. & Montelaro, R. C. (2002). Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype. J Virol 76, 10588-10597.
14. Hussain, K. A., Issel, C. J., Schnorr, K. L., Rwambo, P. M. & Montelaro, R. C. (1987). Antigenic analysis of equine infectious anemia virus (EIAV) variants by using monoclonal antibodies: epitopes of glycoprotein gp90 of EIAV stimulate neutralizing antibodies. J Virol 61, 2956-2961.
15. Hussain, K. A., Issel, C. J., Schnorr, K. L., Rwambo, P. M., West, M. & Montelaro, R. C. (1988). Antigenic mapping of the envelope proteins of equine infectious anemia virus: identification of a neutralization domain and a conserved region on glycoprotein 90. Arch Virol 98, 213-224.
16. Issel, C. J., Adams, W. V., Jr, Meek, L. & Ochoa, R. (1982). Transmission of equine infectious anemia virus from horses without clinical signs of disease. J Am Vet Med Assoc 180, 272-275.
17. Johnson, W. E. & Desrosiers, R. C. (2002). Viral persistance: HIV's strategies of immune system evasion. Annu Rev Med 53, 499-518.
18. Klenerman, P. & Zinkernagel, R. M. (1998). Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 394, 482-485.
19. Kohler, H., Muller, S. & Nara, P. L. (1994). Deceptive imprinting in the immune response against HIV-1. Immunol Today 15, 475-478.
20. Kono, Y., Hirasawa, K., Fukunaga, Y. & Taniguchi, T. (1976). Recrudescence of equine infectious anemia by treatment with immunosuppressive drugs. Natl Inst Anim Health Q (Tokyo) 16, 8-15.
21. Kundu, S. K., Dupuis, M., Sette, A., Celis, E., Dorner, F., Eibl, M. & Merigan, T. C. (1998). Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization. AIDS Res Hum Retrovir 14, 1669-1678.
22. Leroux, C., Issel, C. J. & Montelaro, R. C. (1997). Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony. J Virol 71, 9627-9639.
23. Leroux, C., Craigo, J. K., Issel, C. J. & Montelaro, R. C. (2001). Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies. J Virol 75, 4570-4583.
24. Li, F., Craigo, J. K., Howe, L., Steckbeck, J. D., Cook S., Issel, C. & Montelaro, R. C. (2003). A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J Virol 77, 7244-7253.
25. Lichtenstein, D. L., Issel, C. J. & Montelaro, R. C. (1996). Genomic quasispecies associated with the initiation of infection and disease in ponies experimentally infected with equine infectious anemia virus. J Virol 70, 3346-3354.
26. Locher, C. P., Grant, R. M., Collisson, E. A., Reyes-Teran, G., Elbeik, T., Kahn, J. O. & Levy, J. A. (1999). Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination. AIDS Res Hum Retroviruses 15, 1685-1689.
27. Lue, J., Hsu, M., Yang, D., Marx, P., Chen, Z. & Cheng-Mayer, C. (2002). Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1. J Virol 76, 10299-10306.
28. Ly, A. & Stamatatos, L. (2000). V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J Virol 74, 6769-6776.
29. Malenbaum, S. E., Yang, D., Cavacini, L., Posner, M., Robinson, J. & Cheng-Mayer, C. (2000). The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. J Virol 74 11008-11016.
30. McGuire, T. C., Fraser, D. G. & Mealey, R. H. (2002). Cytotoxic T lymphocytes and neutralizing antibody in the control of equine infectious anemia virus. Viral Immunol 15, 521-531.
31. Mealey, R. H., Fraser, D. G., Oaks, J. L., Cantor, G. H. & McGuire, T. C. (2001). Immune reconstitution prevents continuous equine infectious anemia virus replication in an Arabian foal with severe combined immunodeficiency: lessons for control of lentiviruses. Clin Immunol 101, 237-247.
32. Mealey, R. H., Zhang, B., Leib, S. R., Littke, M. H. & McGuire, T. C. (2003). Epitope specificity is critical for high and moderate avidity cytotoxic T lymphocytes associated with control of viral load and clinical disease in horses with equine infectious anemia virus. Virology 313, 537-552.
33. Mongkolsapaya, J., Dejnirattisai, W., Xu, X. N. & 11 other authors (2003). Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 9, 921-927.
34. Montefiori, D. C., Hill, T. S., Vo, H. T., Walker, B. D. & Rosenberg, E. S. (2001). Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immuno-deficiency virus type 1 infection. J Virol 75, 10200-10207.
35. Montelaro, R. C., Parekh, B., Orrego, A. & Issel, C. J. (1984). Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus. J Biol Chem 259, 10539-10544.
36. Montelaro, R., Ball, J. M. & Rushlow, K. (1993). Equine Retroviruses. In The Retroviridae, pp. 257-360. Edited by J. A. Levy. New York: Plenum.
37. Montelaro, R. C., Grund, C., Raabe, M., Woodson, B., Cook, R. F., Cook, S. & Issel, C. J. (1996). Characterization of protective and enhancing immune responses to equine infectious anemia virus resulting from experimental vaccines. AIDS Res Hum Retroviruses 12, 413-415.
38. Montelaro, R. C., Cole, K S. & Hammond, S. A. (1998). Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development. AIDS Res Hum Retroviruses 14, S255-S259.
39. Nara, P. L. & Garrity, R. (1998). Deceptive imprinting: a cosmopolitan strategy for complicating vaccination. Vaccine 16 1780-1787.
40. Ortiz, G. M., Nixon, D. F., Trkola, A. & 16 other authors (1999). HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 104, R13-18.
41. Ortiz, G. M., Wellons, M., Brancato, J. & 9 other authors (2001). Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A 98 13288-13293.
42. Payne, S. L., Fang, F. D., Liu, C. P., Dhruva, B. R., Rwambo, P., Issel, C. J. & Montelaro, R. C. (1987). Antigenic variation and lentivirus persistence: variations in envelope gene sequences during EIAV infection resemble changes reported for sequential isolates of HIV. Virology 161, 321-331.
43. Perryman, L. E., O'Rourke, K. I. & McGuire, T. C. (1988) Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection. J Virol 62, 3073-3076.
44. Polzer, S., Dittmar, M. T., Schmitz, H. & Schreiber, M. (2002). The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. Virology 304, 70-80.
45. Quinones-Kochs, M. I., Buonocore, L. & Rose, J. K. (2002) Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J Virol 76, 4199-4211.
46. Rwambo, P. M., Issel, C. J., Adams, W. V., Jr, Hussain, K. A., Miller, M. & Montelaro, R. C. (1990a). Equine infectious anemia virus (EIAV) humoral responses of recipient ponies and antigenic variation during persistent infection. Arch Virol 111, 199-212.
47. Rwambo, P. M., Issel, C. J., Hussain, K. A. & Montelaro, R. C. (1990b). In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV). Arch Virol 111, 275-280.
48. Singh, R. A., Rodgers, J. R. & Barry, M. A. (2002). The role of T cell antagonism and original antigenic sin in genetic immunization. J Immunol 169, 6779-6786.
49. Tschetter, J. R., Byrne, K. M., Perryman, L. E. & McGuire, T. C. (1997). Control of equine infectious anemia virus is not dependent on ADCC mediating antibodies. Virology 230, 275-280.
50. Tsuchiya, H., Furukawa, M., Matsui, M., Katsuki, K. & Inouye, S. (2000). 'Original antigenic sin' phenomenon in neutralizing antibody responses in children with enterovirus meningitis. J Clin Virol 19, 205-207.
51. + T lymphocyte depletion in normal and equine infectious anaemia virus-carrier horses. J Gen Virol 75 959-968.
52. Verschoor, E. J., Davis, D., van Gils, M. & 9 other authors (1999). Efforts to broaden HIV-1-specific immunity by boosting with heterologous peptides or envelope protein and the influence of prior exposure to virus. J Med Primatol 28, 224-232.
53. Zhang, W., Lonning, S. M. & McGuire, T. C. (1998). Gag protein epitopes recognized by ELA-A-restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus infection. J Virol 72, 9612-9620.
54. Zheng, Y. H., Nakaya, T., Sentsui, H., Kameoka, M., Kishi, M., Hagiwara, K., Takahashi, H., Kono, Y. & Ikuta, K. (1997). Insertions, duplications and substitutions in restricted gp90 regions of equine infectious anaemia virus during febrile episodes in an experimentally infected horse. J Gen Virol 78, 807-820.